Suven Life Sciences gets patents for neurological drug

The drug firm has a total of six granted patents from Israel, 17 from Japan and 20 from South Africa

Drug firm Suven Life Sciences today said it has been granted a patent each by Israel, Japan and South Africa for a drug used to treat neuro-degenerative diseases.

Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.

In a BSE filing, the company said it has been granted "one product patent from Israel, one product patent from Japan and one product patent from South Africa corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".

Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."

With these, Suven has a total of six granted patents from Israel, 17 from Japan and 20 from South Africa.

"These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.

"Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II," Suven said.

Meanwhile, Suven Life Sciences was trading 3.71 per cent up in the morning trade at Rs 234.75 on BSE.